The estimated Net Worth of Jon P Stonehouse is at least $11.2 Milion dollars as of 13 May 2024. Mr. Stonehouse owns over 30,000 units of Biocryst Pharmaceuticals stock worth over $8,717,662 and over the last 18 years he sold BCRX stock worth over $166,696. In addition, he makes $2,284,300 as President, Chief Executive Officer a Director at Biocryst Pharmaceuticals.
Jon has made over 32 trades of the Biocryst Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of BCRX stock worth $166,500 on 13 May 2024.
The largest trade he's ever made was exercising 297,573 units of Biocryst Pharmaceuticals stock on 1 December 2022 worth over $422,554. On average, Jon trades about 19,218 units every 70 days since 2007. As of 13 May 2024 he still owns at least 1,127,770 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Stonehouse stock trades at the bottom of the page.
Jon P. Stonehouse serves as President, Chief Executive Officer, Director of the Company. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and aquisitions, global licensing and business development, corporate strategy and alliance management. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck &Co., Inc. In 2008 and 2011, respectively, Mr. Stonehouse joined the Advisory Boards of Precision Biosciences, Inc., a private biotechnology company and Genscript, a private bioservices company. Also in December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota. As Chief Executive Officer and President of BioCryst, Mr. Stonehouse brings to the Board an intimate knowledge of our business, and his executive experience in a variety of capacities at major pharmaceutical companies provides industry-specific operational experience that is beneficial to the Board.
As the President, Chief Executive Officer a Director of Biocryst Pharmaceuticals, the total compensation of Jon Stonehouse at Biocryst Pharmaceuticals is $2,284,300. There are no executives at Biocryst Pharmaceuticals getting paid more.
Jon Stonehouse is 59, he's been the President, Chief Executive Officer a Director of Biocryst Pharmaceuticals since 2007. There are 10 older and 11 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
Jon's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... a Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: